Linked Life Data

18035926

Source:http://linkedlifedata.com/resource/pubmed/id/18035926

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-11-26
pubmed:abstractText
Numerous large clinical trials have been carried out over the past several years testing the ability of the antioxidant vitamin E to prevent diabetic cardiovascular disease. Meta-analysis of these studies has demonstrated that vitamin E does not provide any cardiovascular protection and may be associated with an increase in mortality. However, these studies did not address possible benefit to subgroups with increased oxidative stress. In this review we provide supporting clinical evidence and a mechanistic basis for utilizing a genetic marker, the haptoglobin genotype, in determining whether vitamin E therapy may or may not be beneficial for a given patient with diabetes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1744-8344
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1105-11
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
pubmed:affiliation
Technion-Israel Institute of Technology, Department of Cell Biology and Anatomy, Technion Faculty of Medicine, PO Box 9649, Haifa, Israel. alevy@tx.technion.ac.il
pubmed:publicationType
Journal Article, Review